Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25636046 | 0.96 | TLR7 (0.80) | TLR7TLR8 | |
| SCHEMBL13721540 | 0.94 | TLR7 (0.68) | TLR7TLR8 | |
| SCHEMBL13722028 | 0.93 | TLR7 (0.82) | TLR7TLR8 | |
| SCHEMBL18680036 | 0.91 | TLR7 (0.85) | TLR7TLR8 | |
| SCHEMBL18429392 | 0.90 | TLR7 (0.86) | TLR7TLR8 | |
| SCHEMBL13722011 | 0.90 | TLR7 (0.70) | TLR7TLR8 | |
| SCHEMBL13721476 | 0.90 | TLR7 (0.63) | TLR7TLR8 | |
| SCHEMBL13721979 | 0.90 | TLR7 (0.63) | TLR7TLR8 | |
| SCHEMBL14516472 | 0.88 | TLR7 (0.70) | TLR7TLR8 | |
| SCHEMBL13721633 | 0.88 | TLR7 (0.66) | TLR7TLR8 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230372442-A1 | Formulated and/or Co-Formulated Liposome Compositions Containing Toll-like Receptor(\"TLR\") Agonist Prodrugs Useful In The Treatment of Cancer and Methods Thereof | NAMMI THERAPEUTICS, INC. | 2023-11-23 | — | — | US | disclosed |
| US-20230372442-A1 | Formulated and/or Co-Formulated Liposome Compositions Containing Toll-like Receptor(\"TLR\") Agonist Prodrugs Useful In The Treatment of Cancer and Methods Thereof | NAMMI THERAPEUTICS, INC. | 2023-11-23 | — | — | US | disclosed |
| US-20230277621-A1 | Formulated and/or co-formulated liposome compositions containing toll-like receptor (\"TLR\") agonist prodrugs useful in the treatment of cancer and methods thereof | NAMMI THERAPEUTICS, INC. | 2023-09-07 | — | — | US | disclosed |
| US-20230277621-A1 | Formulated and/or co-formulated liposome compositions containing toll-like receptor (\"TLR\") agonist prodrugs useful in the treatment of cancer and methods thereof | NAMMI THERAPEUTICS, INC. | 2023-09-07 | — | — | US | disclosed |
| US-11744874-B2 | Formulated and/or co-formulated liposome compositions containing toll-like receptor (“TLR”) agonist prodrugs useful in the treatment of cancer and methods thereof | NAMMI THERAPEUTICS, INC. (US) | 2023-09-05 | — | — | US | disclosed |
| US-11744874-B2 | Formulated and/or co-formulated liposome compositions containing toll-like receptor (“TLR”) agonist prodrugs useful in the treatment of cancer and methods thereof | NAMMI THERAPEUTICS, INC. (US) | 2023-09-05 | — | — | US | disclosed |
| US-20230270819-A1 | Formulated and/or Co-Formulated Liposome Compositions Containing Toll--Like Receptor (\"TLR\") Agonist Prodrugs Useful In The Treatment of Cancer and Methods Thereof | NAMMI THERAPEUTICS, INC. | 2023-08-31 | — | — | US | disclosed |
| US-20230270819-A1 | Formulated and/or Co-Formulated Liposome Compositions Containing Toll--Like Receptor (\"TLR\") Agonist Prodrugs Useful In The Treatment of Cancer and Methods Thereof | NAMMI THERAPEUTICS, INC. | 2023-08-31 | — | — | US | disclosed |
| US-11679141-B2 | Formulated and/or co-formulated liposome compositions containing toll-like receptor (“TLR”) agonist prodrugs useful in the treatment of cancer and methods thereof | NAMMI THERAPEUTICS, INC. (US) | 2023-06-20 | — | — | US | disclosed |
| US-11679141-B2 | Formulated and/or co-formulated liposome compositions containing toll-like receptor (“TLR”) agonist prodrugs useful in the treatment of cancer and methods thereof | NAMMI THERAPEUTICS, INC. (US) | 2023-06-20 | — | — | US | disclosed |
| US-20220193187-A1 | Formulated and/or co-furmulated liposome compositions containing toll-like receptor (\"TLR\") agonist prodrugs useful in the treatment of cancer and methods thereof | NAMMI THERAPEUTICS, INC. | 2022-06-23 | — | — | US | disclosed |
| US-20210187066-A1 | Formulated and/or co-formulated liposome compositions containing toll-like receptor (\"TLR\") agonist prodrugs useful in the treatment of cancer and methods thereof | NAMMI THERAPEUTICS, INC. | 2021-06-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11744874-B2 | Formulated and/or co-formulated liposome compositions containing toll-like receptor (“TLR”) agonist prodrugs useful in the treatment of cancer and methods thereof | TLR1, TLR4, TLR7 | TLR7 3/4885TLR8 8/4885 |
| US-20230372442-A1 | Formulated and/or Co-Formulated Liposome Compositions Containing Toll-like Receptor(\"TLR\") Agonist Prodrugs Useful In The Treatment of Cancer and Methods Thereof | TLR1, TLR7, TLR4 | TLR7 2/4885TLR8 8/4885 |
| US-20220193187-A1 | Formulated and/or co-furmulated liposome compositions containing toll-like receptor (\"TLR\") agonist prodrugs useful in the treatment of cancer and methods thereof | TLR1, TLR9, TLR4 | TLR7 4/4885TLR8 8/4885 |
| US-20230270819-A1 | Formulated and/or Co-Formulated Liposome Compositions Containing Toll--Like Receptor (\"TLR\") Agonist Prodrugs Useful In The Treatment of Cancer and Methods Thereof | TLR1, TLR7, TLR4 | TLR7 2/4885TLR8 8/4885 |
| US-11679141-B2 | Formulated and/or co-formulated liposome compositions containing toll-like receptor (“TLR”) agonist prodrugs useful in the treatment of cancer and methods thereof | TLR1, TLR4, TLR7 | TLR7 3/4885TLR8 8/4885 |
| US-20230277621-A1 | Formulated and/or co-formulated liposome compositions containing toll-like receptor (\"TLR\") agonist prodrugs useful in the treatment of cancer and methods thereof | TLR1, TLR7, TLR4 | TLR7 2/4885TLR8 8/4885 |
| US-20210187066-A1 | Formulated and/or co-formulated liposome compositions containing toll-like receptor (\"TLR\") agonist prodrugs useful in the treatment of cancer and methods thereof | TLR1, TLR7, TLR4 | TLR7 2/4885TLR8 8/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.